| Schedule of components of income tax expense |
| Schedule of components of income tax expense
|
|
|
|
|
|
|
| |
|
2022 |
|
|
2021 |
|
| |
|
|
|
|
|
|
| Expected federal income tax benefit at statutory rate |
|
$ |
7,184,840 |
|
|
$ |
8,426,269 |
|
| Non-deductible expenses |
|
|
(288,249 |
) |
|
|
(224,189 |
) |
| Research and development credit |
|
|
595,244 |
|
|
|
537,705 |
|
| Return to provision true up |
|
|
93,285 |
|
|
|
(94,707 |
) |
| Change in valuation allowance |
|
|
(7,585,120 |
) |
|
|
(8,834,492 |
) |
| Income tax benefit |
|
$ |
– |
|
|
$ |
– |
|
|
| Schedule of deferred tax assets and liabilities |
| Schedule of deferred tax assets and liabilities
|
|
|
|
|
|
|
| |
|
2022 |
|
|
2021 |
|
| Deferred tax assets |
|
|
|
|
|
|
|
|
| Net operating losses |
|
$ |
9,106,430 |
|
|
$ |
5,078,075 |
|
| Depreciation and amortization |
|
|
1,502,868 |
|
|
|
46,030 |
|
| Research & development credit |
|
|
1,308,956 |
|
|
|
592,276 |
|
| Lease liability |
|
|
322,167 |
|
|
|
466,980 |
|
| Stock-based compensation |
|
|
3,103,037 |
|
|
|
2,872,973 |
|
| Inventory |
|
|
1,290,968 |
|
|
|
– |
|
| Accrued expenses |
|
|
233,284 |
|
|
|
478,171 |
|
| Capital loss carryover |
|
|
261,922 |
|
|
|
– |
|
| Other |
|
|
177,074 |
|
|
|
336 |
|
| Total |
|
|
17,306,705 |
|
|
|
9,534,840 |
|
| Valuation allowance |
|
|
(16,661,612 |
) |
|
|
(9,076,492 |
) |
| Net deferred tax asset |
|
|
645,093 |
|
|
|
458,348 |
|
| Deferred tax liabilities |
|
|
|
|
|
|
|
|
| Prepaid expenses |
|
|
(328,836 |
) |
|
|
– |
|
| Right-of-use assets |
|
|
(316,257 |
) |
|
|
(458,348 |
) |
| Total net deferred taxes Deferred tax liabilities |
|
$ |
– |
|
|
$ |
– |
|
|